To this end, therapeutic approaches such as combination checkpoint inhibition (anti-PD-1/PD-L1 plus anti–Tim-3), novel bispecific antibodies, or dual-targeting agents have emerged as critical avenues for improving the efficacy of cancer immunotherapy (22–24). The gene discussed is HAVCR2; the disease is cancer.